All In Biotech

Drug Trial Radar · NCT02878603

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Oct 6, 2016

Primary completion

Oct 23, 2020

Study completion Oct 23, 2020

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

Conditions

  • Acquired Thrombotic Thrombocytopenic Purpura

Interventions

  • CaplacizumabBiological

  • Standard of CareOther

    • PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related EventsTime frame: From Baseline up to 36 months
  2. Number of Acquired Thrombotic Thrombocytopenic Purpura-related EventsTime frame: From Baseline up to 36 months
  3. Time to First Acquired Thrombotic Thrombocytopenic Purpura-related EventsTime frame: From Baseline up to 36 months
  4. Number of Participants With aTTP Related Deaths Reported During the StudyTime frame: From Baseline up to 36 months
  5. Percentage of Participants With Recurrence of Disease (aTTP)Time frame: From Baseline up to 36 months
  6. Number of Disease (aTTP) Recurrence Reported During the StudyTime frame: From Baseline up to 36 months
  7. Time to Recurrence of Disease (aTTP)Time frame: From Baseline up to 36 months
  8. Percentage of Participants With Major Thromboembolic Events Including Thrombotic Thrombocytopenic Purpura (TTP)Time frame: From Baseline up to 36 months
  9. Number of Major Thromboembolic Events Including Thrombotic Thrombocytopenic PurpuraTime frame: From Baseline up to 36 months
  10. Time to First Major Thromboembolic EventTime frame: From Baseline up to 36 months
  11. Cognitive Function: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Absolute Scores at Baseline, 36 Months Follow-up Visit, and Change From Baseline in RBANS Total Score at 36 Months Follow-up VisitTime frame: Baseline, 36 Months follow-up visit
  12. Health-Related Quality of Life (HRQoL): Change From Baseline in Headache Impact Test (HIT-6) Total Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  13. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire (SF-36) Health Survey - Physical Functioning Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  14. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Role Functioning/Physical Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  15. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Role Functioning/Emotional Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  16. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Energy/Fatigue Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  17. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Emotional Well-being Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  18. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Social Functioning Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  19. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Pain Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  20. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - General Health Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  21. Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Change in Health Status Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
  22. Percentage of Participants With Drug-induced Treatment-emergent (TE) Anti-drug Antibodies (ADA) Positive ResponseTime frame: From Baseline up to 36 months
  23. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Baseline up to 36 months

Locations

45 sites in 13 countries. Site status is shown where the registry gives one.

  • Investigator site

    St Louis, Missouri

  • Investigator site

    Valhalla, New York

  • Investigator Site

    Durham, North Carolina

  • Investigator Site

    Columbus, Ohio

  • Investigator Site

    Oklahoma City, Oklahoma

  • Investigator site

    Pittsburgh, Pennsylvania

  • Investigator Site

    Charleston, South Carolina

  • Investigator site

    Greenville, South Carolina

  • Investigator site

    Vienna, Austria

  • Investigator site

    Antwerp, Belgium

  • Investigator site

    Brussels, Belgium

  • Investigator site

    La Louvière, Belgium

  • Investigator site

    Leuven, Belgium

  • Investigator Site

    Halifax, Canada

  • Investigator Site

    Québec, Canada

  • Investigator Site

    Toronto, Canada

  • Investigator Site

    Brno, Czechia

  • Investigator Site

    Olomouc, Czechia

  • Investigator site

    Caen, France

  • Investigator site

    Lille, France

  • Investigator site

    Marseille, France

  • Investigator site 1

    Paris, France

  • Investigator site 2

    Paris, France

  • Investigator Site

    Budapest, Hungary

  • Investigator Site

    Debrecen, Hungary

  • Investigator Site

    Haifa, Israel

  • Investigator Site

    Jerusalem Region, Israel

  • Investigator Site

    Nahariya, Israel

  • Investigator Site

    Catania, Italy

  • Investigator Site

    Milan, Italy

  • Investigator site

    Pesaro, Italy

  • Investigator Site

    Rome, Italy

  • Investigator Site

    Vicenza, Italy

  • Investigator Site 1

    Barcelona, Spain

  • Investigator Site 2

    Barcelona, Spain

  • Investigator site

    Seville, Spain

  • Investigator Site 2

    Valencia, Spain

  • Investyigator Site 1

    Valencia, Spain

  • Investigator site

    Bern, Switzerland

  • Investigator site

    Ankara, Turkey (Türkiye)

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.